General Medicine and Primary Care - Global Cardiology Academy

17-32 of 78

Rethinking Risk in Heart Failure with Preserved Ejection Fraction
Rethinking Risk in Heart Failure with Preserved Ejection Fraction
Heart Matters
Rethinking Risk in Heart Failure with Preserved Ejection Fraction
Alexandria May, PharmD, BCPS; Javed Butler, MD, MPH, MBA
- Alexandria May, PharmD, BCPS
- Javed Butler, MD, MPH, MBA
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Heart Matters
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Alexandria May, PharmD, BCPS; Javed Butler, MD, MPH, MBA
- Alexandria May, PharmD, BCPS
- Javed Butler, MD, MPH, MBA
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Heart Matters
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Making UACR a Routine Part of Diabetes Care
Making UACR a Routine Part of Diabetes Care
Heart Matters
Making UACR a Routine Part of Diabetes Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
Hallie Blevins, PhD
- Hallie Blevins, PhD
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Scott Solomon, MD
0.25 credits
- Scott Solomon, MD
0.25 credits
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart Matters
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart Matters
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Heart Matters
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Heart Matters
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Heart Matters
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Heart Matters
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Improving Lipid Management Through Equity-Focused Clinical Strategies
Improving Lipid Management Through Equity-Focused Clinical Strategies
Heart Matters
Improving Lipid Management Through Equity-Focused Clinical Strategies
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Heart Matters
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Heart Matters
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment

2/5